Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma

NCT04510636 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

37

Enrollment

OTHER

Sponsor class

Conditions

Classical Hodgkin Lymphoma
Relapsed Cancer
Refractory Cancer

Interventions

DRUG: Pembrolizumab
DRUG: Bendamustine Hydrochloride

Sponsor

University Health Network, Toronto